Agrin is a novel oncogenic protein in thyroid cancer.
agrin
invasion
migration
neutrophil infiltration
proliferation
thyroid cancer
viability
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
27
04
2023
accepted:
07
09
2023
medline:
11
10
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
epublish
Résumé
Agrin (AGRN) is a matricellular glycoprotein involved in extracellular signal transduction. AGRN is involved in tumorigenesis and cancer progression; however, the role of AGRN in thyroid cancer (TC) remains unclear. In the present study, using cell lines derived from various subtypes of TC including CGTH, FTC-133 and BcPAP and transcriptomic data from patients with TC, the role of AGRN in TC was analyzed by migration, invasion, viability and proliferation assays as well as Western blot with EMT markers. AGRN expression was significantly increased in thyroid tumors and cell lines derived from various TC subtypes. The highest AGRN expression was found in follicular and papillary thyroid carcinoma subtypes. Immunocytochemistry revealed nuclear AGRN localization in normal (NTHY) and TC cells. Silencing of AGRN decreased viability, proliferation, migration and invasion of TC cell lines by upregulating vimentin and downregulating N-cadherin and E-cadherin. Furthermore, the expression of AGRN was associated with neutrophil infiltration in thyroid tumors. In conclusion, the present results indicated that increased AGRN expression promoted tumorigenic phenotypes of TC cells, while AGRN expression was associated with immune infiltration in thyroid tumors. AGRN may represent a target for future cancer therapy and requires further evaluation.
Identifiants
pubmed: 37818129
doi: 10.3892/ol.2023.14070
pii: OL-26-5-14070
pmc: PMC10561154
doi:
Types de publication
Journal Article
Langues
eng
Pagination
483Informations de copyright
Copyright: © Adamiok-Ostrowska et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Endocrinol Metab (Seoul). 2013 Sep;28(3):192-8
pubmed: 24396678
J Recept Signal Transduct Res. 2021 Aug;41(4):363-370
pubmed: 32862766
Blood. 2014 Jul 31;124(5):710-9
pubmed: 24923297
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Mol Cancer Ther. 2011 Mar;10(3):385-94
pubmed: 21388974
J Natl Compr Canc Netw. 2022 Aug;20(8):925-951
pubmed: 35948029
Front Immunol. 2020 Dec 02;11:553967
pubmed: 33343560
Endocr Rev. 2016 Apr;37(2):135-87
pubmed: 26862888
Endocrinol Metab (Seoul). 2020 Dec;35(4):696-715
pubmed: 33261309
Genes (Basel). 2020 Nov 12;11(11):
pubmed: 33198372
Trends Neurosci. 1998 Jan;21(1):22-7
pubmed: 9464682
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Eur J Biochem. 1998 May 15;254(1):123-8
pubmed: 9652404
Nat Commun. 2015 Jan 29;6:6184
pubmed: 25630468
Curr Opin Oncol. 2022 Jan 1;34(1):9-18
pubmed: 34636352
J Immunol. 2007 Dec 1;179(11):7975-83
pubmed: 18025246
J Clin Med. 2020 Dec 28;10(1):
pubmed: 33379135
Int J Cancer. 2016 Jul 15;139(2):446-56
pubmed: 26939802
Neuron. 2008 Oct 23;60(2):285-97
pubmed: 18957220
Cell Stem Cell. 2015 Nov 5;17(5):527-42
pubmed: 26593959
Endocrinology. 2006 Jan;147(1):295-305
pubmed: 16223867
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Cancer Res. 2018 Aug 1;78(15):4138-4149
pubmed: 29871935
Front Neurol. 2020 Nov 30;11:596981
pubmed: 33329350
Cancer Res. 2020 Apr 1;80(7):1461-1474
pubmed: 32029550
Pol J Pathol. 2019;70(3):198-204
pubmed: 31820863
Front Mol Biosci. 2021 Nov 01;8:714053
pubmed: 34790698
J Int Med Res. 2021 May;49(5):3000605211009722
pubmed: 34018826
PLoS One. 2014 Dec 15;9(12):e115004
pubmed: 25506919
Case Rep Med. 2013;2013:813167
pubmed: 24307906
Endocr Relat Cancer. 2008 Dec;15(4):1069-74
pubmed: 18719091
Blood. 2012 Jun 7;119(23):5502-11
pubmed: 22517892
Nat Commun. 2022 Mar 24;13(1):1588
pubmed: 35332119
Cancers (Basel). 2021 Jun 26;13(13):
pubmed: 34206867
Cell Rep. 2019 Jul 23;28(4):949-965.e7
pubmed: 31340156
Front Oncol. 2019 Nov 15;9:1146
pubmed: 31799175
Endocrinol Metab (Seoul). 2022 Oct;37(5):703-718
pubmed: 36193717
Case Rep Oncol Med. 2017;2017:4276435
pubmed: 29158933
Nature. 2017 Jul 13;547(7662):179-184
pubmed: 28581497
J Clin Endocrinol Metab. 2012 May;97(5):1474-82
pubmed: 22399513
Endocrinology. 2001 Jul;142(7):3152-62
pubmed: 11416038
Front Endocrinol (Lausanne). 2022 May 26;13:887906
pubmed: 35692397
Oncoimmunology. 2017 Feb 21;6(4):e1293211
pubmed: 28507798
Front Oncol. 2022 Jan 17;11:804418
pubmed: 35111682
Br J Cancer. 2018 Jun;118(12):1628-1638
pubmed: 29872149
Mol Cell Proteomics. 2022 Apr;21(4):100216
pubmed: 35202840
J Clin Invest. 2010 Apr;120(4):1151-64
pubmed: 20237412
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
BMC Cancer. 2017 Mar 28;17(1):225
pubmed: 28351395
Cell Rep. 2017 Mar 7;18(10):2464-2479
pubmed: 28273460
Cell. 2008 Oct 17;135(2):334-42
pubmed: 18848351
Ann R Coll Surg Engl. 2017 Feb;99(2):151-154
pubmed: 27659362
Nat Commun. 2019 Dec 12;10(1):5679
pubmed: 31831737
Hum Pathol. 2017 Oct;68:193-202
pubmed: 28882699
J Bone Oncol. 2020 Feb 19;21:100282
pubmed: 32154098
Front Endocrinol (Lausanne). 2022 Mar 01;13:791826
pubmed: 35299967
Neoplasia. 2022 Mar;25:18-27
pubmed: 35078134
Int J Mol Sci. 2022 Mar 17;23(6):
pubmed: 35328683
Cancers (Basel). 2021 Apr 01;13(7):
pubmed: 33915699
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
PLoS One. 2018 Jun 28;13(6):e0199740
pubmed: 29953504
Cancer Res. 2005 Oct 1;65(19):8896-904
pubmed: 16204061